Last reviewed · How we verify

NCT05835791: END VT

END - VT Cohort Study

Recruiting now Last updated 16 July 2024
What this trial tests

trial in Ventricular Tachycardia in 2,454 participants. Currently enrolling.

Timeline
12 January 2024
Primary endpoint
30 April 2028
30 April 2029

Quick facts

Lead sponsorNova Scotia Health Authority
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,454
Start date12 January 2024
Primary completion30 April 2028
Estimated completion30 April 2029
Sites3 locations across Canada

Conditions studied

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

18 and older, any sex, with Ventricular Tachycardia or Implantable Defibrillator User. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased/scarred cardiac muscle) have the highest risk of SCD (\<1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death. The primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ventricular Tachycardia

Currently open trials in the same condition.

Other Nova Scotia Health Authority trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05835791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing